Log In
Wednesday 23rd May 2018

EU suicide warning on diet pill

20th July 2007

The European drug regulator has warned of an increased risk of suicide among those who take the weight-loss drug Acomplia alongside anti-depressants.


The European Medicines Agency said patients with severe depression should not be prescribed Acomplia, which is manufactured by France-based pharma giant sanofi-aventis.

Acomplia, whose generic name is rimonabant, was touted as a miracle pill after it was found to aid weight-loss of up to 10% in dieters, as well as helping them quit smoking.

The warning comes only weeks after an committee advising the US Food and Drug Administration (FDA) said the drug should be banned, also citing an increased risk of suicide.

One study showed that of 120 patients taking the drug, two have committed suicide and one was reported to be considering it. One man had also tried to strangle his daughter.

The agency stopped short of calling for the drug to be banned, but said conditions should be placed on its prescription, and it warned that anyone who developed depression while taking rimonabant should stop taking it.

While the committee examining the drug concluded that the benefits of the drug outweighed the risks, the UK's regulatory body said it would write to doctors informing them about the updated prescribing information.

The drug rimonabant was first sold in the United Kingdom soon after the European Commission approved it.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: EU suicide warning on diet pill
Author: Jess Laurence
Article Id: 3521
Date Added: 20th Jul 2007


Recent Related Articles

Britain should go on a diet


Add to scrapbook
Show Comments
Add comment
Find all related articles


M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2018